FoundationOne CDx
Foundation Medicine, Inc. · Decision date Sep 16, 2026
What did the FDA approve?
FDA records P170019/S069 as a supplement to PMA P170019, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 16, 2026.
FDA approval order statement
Approval to update the F1CDx labeling to include the results of the supplemental clinical data submitted in the Post-Approval Study (PAS) Report
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Pathology
- Decision date
- Sep 16, 2026
- FDA change category
- Labeling Change - PAS
Regulatory record facts
- Identifier
- P170019/S069
- Regulatory pathway
- PMA supplement
- Applicant
- Foundation Medicine, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Foundation Medicine, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170019 · Original PMA
FoundationOne CDx
P170019/S069 received
Application receipt date recorded by FDA.
P170019/S069 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P170019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FoundationOne CDxP170019 | Foundation Medicine, Inc. | PMA approval | Nov 30, 2017 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Foundation Medicine, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 400 Summer St., Boston, MA, 02210
Sources and methodology
- Original FDA record: P170019/S069
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


